All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer beta variant (B.1.351 / 501Y.V2, South Africa) children delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers immunodepression kidney transplant recipients obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC positive for SARS-Cov-2 at baseline solid cancer solid organ transplant recipients subjects at risk
mRNA vaccine in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 6 months symptomatic COVIDdetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 0.09 [0.07; 0.11]
0.09 [0.07 ; 0.11 ] BNT162b2 phase 3 (C4591001, Polack), 2020 1 0% 46,077 NA not evaluable confirmed Covid-19, from 1st dosedetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 0.18 [0.13; 0.25]
COVE Moderna/NIH phase 3 (study 301), 2020 0.05 [0.03; 0.09]
0.10 [0.03 ; 0.35 ] BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020 2 93% 70,779 moderate not evaluable deathsdetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 0.50 [0.09; 2.73]
COVE Moderna/NIH phase 3 (study 301), 2020 0.50 [0.02; 14.84]
0.50 [0.11 ; 2.28 ] BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020 2 0% 71,459 moderate not evaluable vaccine efficacy from randomization (ITT)detailed results BNT162b2 phase 3 (C4591001, Polack), 2020 0.18 [0.13; 0.25]
COVE Moderna/NIH phase 3 (study 301), 2020 0.07 [0.04; 0.11]
0.11 [0.04 ; 0.29 ] BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020 2 91% 71,720 moderate not evaluable symptomatic Covid-19detailed results BNT162b2 phase 3 (C4591001, Polack), 2020 0.05 [0.02; 0.10]
COVE Moderna/NIH phase 3 (study 301), 2020 0.06 [0.03; 0.11]
0.05 [0.03 ; 0.09 ] BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020 2 0% 64,730 moderate not evaluable 6 months severe COVID-19detailed results BNT162b2 phase 3 (C4591001, Polack), 2020 0.03 [0.00; 0.46]
0.03 [0.00 ; 0.46 ] BNT162b2 phase 3 (C4591001, Polack), 2020 1 0% NA not evaluable severe COVID-19 occurrencedetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 0.25 [0.01; 5.62]
COVE Moderna/NIH phase 3 (study 301), 2020 0.02 [0.00; 0.27]
0.06 [0.00 ; 0.84 ] BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020 2 38% 70,780 moderate not evaluable vaccine efficacy after dose 1 (and before dose 2)detailed results BNT162b2 phase 3 (C4591001, Polack), 2020 0.48 [0.32; 0.71]
0.48 [0.32 ; 0.71 ] BNT162b2 phase 3 (C4591001, Polack), 2020 1 0% 43,355 NA not evaluable related AE (TRAE)detailed results BNT162b2 phase 3 (C4591001, Polack), 2020 4.91 [4.58; 5.26]
4.91 [4.58 ; 5.26 ] BNT162b2 phase 3 (C4591001, Polack), 2020 1 0% 43,252 NA not evaluable related SAE (TRSAE)detailed results BNT162b2 phase 3 (C4591001, Polack), 2020 8.00 [0.42; 151.43]
8.00 [0.42 ; 151.43 ] BNT162b2 phase 3 (C4591001, Polack), 2020 1 0% 43,252 NA not evaluable serious adverse eventsdetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 1.14 [0.88; 1.47]
COVE Moderna/NIH phase 3 (study 301), 2020 1.04 [0.78; 1.40]
1.10 [0.90 ; 1.33 ] BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020 2 0% 73,603 moderate not evaluable adverse eventsdetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 2.62 [2.49; 2.76]
COVE Moderna/NIH phase 3 (study 301), 2020 1.14 [1.08; 1.20]
1.73 [0.77 ; 3.91 ] BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020 2 100% 73,603 moderate not evaluable life-threatening SAEdetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 0.91 [0.51; 1.65]
0.91 [0.51 ; 1.65 ] BNT162b2 phase 3 (C4591001, Polack), 2020 1 0% 43,252 NA not evaluable severe adverse eventsdetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 1.74 [1.41; 2.14]
1.74 [1.41 ; 2.14 ] BNT162b2 phase 3 (C4591001, Polack), 2020 1 0% 43,252 NA not evaluable appendicitisdetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 2.00 [0.60; 6.65]
COVE Moderna/NIH phase 3 (study 301), 2020 0.67 [0.11; 3.99]
1.42 [0.52 ; 3.86 ] BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020 2 0% 73,799 moderate not evaluable arthralgia, grade 3-4detailed results COVE Moderna/NIH phase 3 (study 301), 2020 18.37 [13.54; 24.91]
18.37 [13.54 ; 24.91 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 30,351 NA not evaluable Bell's palsydetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 7.99 [0.42; 151.24]
COVE Moderna/NIH phase 3 (study 301), 2020 3.00 [0.31; 28.83]
4.32 [0.72 ; 25.96 ] BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020 2 0% 67,937 moderate not evaluable hypersensitivity, all termsdetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 2.17 [0.82; 5.71]
COVE Moderna/NIH phase 3 (study 301), 2020 1.41 [1.15; 1.72]
1.43 [1.18 ; 1.74 ] BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020 2 0% 73,603 moderate not evaluable immediate allergic reactiondetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 1.00 [0.02; 50.42]
1.00 [0.02 ; 50.42 ] BNT162b2 phase 3 (C4591001, Polack), 2020 1 0% 43,448 NA not evaluable lymphadenopathy, anydetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 10.69 [4.63; 24.69]
10.69 [4.63 ; 24.69 ] BNT162b2 phase 3 (C4591001, Polack), 2020 1 0% 37,586 NA not evaluable lymphadenopathy, grade 3-4detailed results COVE Moderna/NIH phase 3 (study 301), 2020 1.00 [0.06; 15.97]
1.00 [0.06 ; 15.97 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 30,351 NA not evaluable musculoskeletal and connective tissue disorders, anydetailed results BNT162b2 phase 3 (C4591001, Polack), 2020 3.65 [3.26; 4.09]
COVE Moderna/NIH phase 3 (study 301), 2020 1.00 [0.06; 15.97]
3.64 [3.25 ; 4.08 ] BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020 2 0% 67,937 moderate not evaluable myalgia, grade 3-4detailed results COVE Moderna/NIH phase 3 (study 301), 2020 27.64 [20.93; 36.50]
27.64 [20.93 ; 36.50 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 30,351 NA not evaluable fever, grade 3-4detailed results COVE Moderna/NIH phase 3 (study 301), 2020 43.29 [17.83; 105.10]
43.29 [17.83 ; 105.10 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 29,242 NA not evaluable local adverse reaction, any, dose 1detailed results BNT162b2 phase 3 (C4591001, Polack), 2020 24.90 [22.13; 28.03]
24.90 [22.13 ; 28.03 ] BNT162b2 phase 3 (C4591001, Polack), 2020 1 0% 8,183 NA not evaluable local adverse reaction, any, dose 2detailed results BNT162b2 phase 3 (C4591001, Polack), 2020 23.04 [20.30; 26.15]
COVE Moderna/NIH phase 3 (study 301), 2020 33.74 [31.59; 36.03]
27.99 [19.26 ; 40.68 ] BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020 2 96% 36,742 moderate not evaluable local adverse reaction, grade 3-4, dose 2detailed results COVE Moderna/NIH phase 3 (study 301), 2020 15.04 [11.83; 19.12]
15.04 [11.83 ; 19.12 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 29,235 NA not evaluable systemic adverse reaction, any, dose 1detailed results BNT162b2 phase 3 (C4591001, Polack), 2020 1.63 [1.50; 1.78]
1.63 [1.50 ; 1.78 ] BNT162b2 phase 3 (C4591001, Polack), 2020 1 0% 8,183 NA not evaluable systemic adverse reaction, any, dose 2detailed results BNT162b2 phase 3 (C4591001, Polack), 2020 4.55 [4.13; 5.01]
COVE Moderna/NIH phase 3 (study 301), 2020 6.69 [6.35; 7.05]
5.53 [3.79 ; 8.06 ] BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020 2 98% 36,749 moderate not evaluable systemic adverse reaction, grade 3-4, dose 2detailed results COVE Moderna/NIH phase 3 (study 301), 2020 9.50 [8.38; 10.77]
9.50 [8.38 ; 10.77 ] COVE Moderna/NIH phase 3 (study 301), 2020 1 0% 29,242 NA not evaluable 0.0 100.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-01 00:39 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 89
- treatments: 806,758,826,755
- roots T: 290